EVAX — Evaxion Biotech A/S Balance Sheet
0.000.00%
Last trade - 00:00- $2.20m
- $6.35m
- $3.34m
Annual balance sheet for Evaxion Biotech A/S, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 5.83 | 32.2 | 13.2 | 5.58 | 5.95 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.21 | 1.34 | 1.09 | 1.07 | 1.82 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 10.9 | 34.7 | 17 | 8.35 | 8.77 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.221 | 5.17 | 4.67 | 4.34 | 3.51 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 12 | 40.2 | 22 | 12.9 | 12.5 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.93 | 4.32 | 3.76 | 7.08 | 4.37 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.93 | 7.73 | 13.7 | 17.6 | 14.1 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 7.04 | 32.4 | 8.3 | -4.73 | -1.65 |
| Total Liabilities & Shareholders' Equity | 12 | 40.2 | 22 | 12.9 | 12.5 |
| Total Common Shares Outstanding |